Novozymes bets on China's green push

Danish biotech firm sees potential in nation's efforts toward carbon goals

Danish biological products provider Novozymes is eager to capture opportunities in China by intensifying its focus on innovation and offering localized biotech solutions, the company said.

China's optimized COVID-19 response measures have supported the development of the private sector, and helped attract more foreign investment, Novozymes said.

Despite headwinds from the pandemic, Novozymes' China business has played an important role in its overall strategy. In 2022, the company's sales grew 9 percent in both emerging and developed markets.